Vascular Endothelial Growth Factor (VEGF) as a Biomarker for Cancer-Associated Venous Thrombosis: A Meta-analysis
TH Open · 10.02.2025 · 09 (CP)
DOI: 10.1055/a-2513-4381 ↗Kurz gefasst
Metaanalyse in der Zeitschrift TH Open, erschienen am 10.02.2025. Verfasst von Alison M Brown und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood Sciences, The Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cancer-associated thrombosis affects between 1 and 20% of all patients diagnosed with cancer and is associated with significant morbidity and a poorer prognosis. Risk assessment scores exist which include the measurement of biomarkers, and which aim to identify patients at a higher risk of developing thrombotic events, but these are poor predictors and rarely used in routine clinical practice. VEGF is a potent angiogenic factor, produced by tumour cells, and released by platelets and is essential for tumour growth and progression. It also plays a role in the promotion of thrombosis through platelet activation and adhesion, and by inducing the expression of tissue factor. Therefore, the potential of VEGF to be used as a biomarker to predict cancer-associated thrombosis requires further investigation. This study reviewed the published literature to determine whether circulating VEGF levels are associated with increased risk of venous thromboembolism in patients with cancer. PubMed and OVID databases were systematically searched according to PRISMA guidelines for relevant papers using the keywords “cancer” AND “thrombosis” AND “VEGF” up to July 2023. Inclusion and exclusion criteria were applied. Seven papers (1,528 participants) were identified and included in the meta-analysis, three of which (922 participants) measured VEGF before a thrombotic event, and the remaining four (606 participants) measured VEGF at the time of the thrombosis. Our results showed that although plasma and serum VEGF tended to be higher in those who subsequently developed thrombosis than those who did not (mean difference 70.2 pg/mL for serum, and 11.44 pg/mL for plasma VEGF, 95% CI −2.39–25.73, p = 0.10), this was not found to be statistically significant. However, analysis of VEGF following blood sampling at the time of thrombosis showed a stronger statistically significant association between increased VEGF levels and presence of thrombosis (mean difference 117.02 pg/mL for serum, and 116.6 pg/mL for plasma VEGF, 95% CI 55.42–190.82, p = 0.0004). Based on current studies, whilst it is increased at the time of thrombosis, VEGF is not effective as a predictive biomarker of CAT.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Blood Sciences, The Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom.
- Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom.
- Haematology Department, The Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom.
- Thrombosis Collective, Leeds Institute of Cardiovascular and Metabolic Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom.
ORCID-Profile: Amanda J Unsworth
Zitieren
APA
Brown, A. M., Nock, S., Musgrave, K., & Unsworth, A. J. (2025). Vascular Endothelial Growth Factor (VEGF) as a Biomarker for Cancer-Associated Venous Thrombosis: A Meta-analysis. TH Open, 09(CP). https://doi.org/10.1055/a-2513-4381
Vancouver
Brown AM, Nock S, Musgrave K, Unsworth AJ. Vascular Endothelial Growth Factor (VEGF) as a Biomarker for Cancer-Associated Venous Thrombosis: A Meta-analysis. TH Open. 2025;09(CP). doi:10.1055/a-2513-4381
BibTeX
@article{Brown2025,
author = {Brown, Alison M and Nock, Sophie and Musgrave, Kathryn and Unsworth, Amanda J},
title = {Vascular Endothelial Growth Factor (VEGF) as a Biomarker for Cancer-Associated Venous Thrombosis: A Meta-analysis},
journal = {TH Open},
year = {2025},
volume = {09},
number = {CP},
doi = {10.1055/a-2513-4381}
}
EUVIMED